Viking Therapeutics CFO Greg Zante's Stock Transactions

The filing details the stock transactions of Greg Zante, the Chief Financial Officer of Viking Therapeutics, Inc. On October 27, 2025, Zante acquired 11,117 shares of common stock at $0 per share, increasing his total holdings to 179,777 shares. This acquisition was part of a performance restricted stock unit award granted on January 3, 2025, which vested upon the achievement of non-financial performance goals. On October 28, 2025, Zante sold 6,185 shares at a weighted average price of $35.0009 per share, reducing his holdings to 173,592 shares. The sale was conducted to satisfy tax withholding obligations related to the vesting of the stock units. The filing also includes footnotes explaining the nature of the transactions and the price ranges for the shares sold.